thermo fisher scientific inc. - TMO

TMO

Close Chg Chg %
512.86 3.19 0.62%

Closed Market

516.05

+3.19 (0.62%)

Volume: 1.96M

Last Updated:

Nov 21, 2024, 3:59 PM EDT

Company Overview: thermo fisher scientific inc. - TMO

TMO Key Data

Open

$514.53

Day Range

507.72 - 516.22

52 Week Range

480.57 - 627.86

Market Cap

$196.16B

Shares Outstanding

382.50M

Public Float

381.91M

Beta

0.79

Rev. Per Employee

N/A

P/E Ratio

32.16

EPS

$16.01

Yield

29.64%

Dividend

$0.39

EX-DIVIDEND DATE

Dec 13, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

1.71M

 

TMO Performance

1 Week
 
-0.05%
 
1 Month
 
-7.49%
 
3 Months
 
-15.39%
 
1 Year
 
4.49%
 
5 Years
 
66.63%
 

TMO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About thermo fisher scientific inc. - TMO

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

TMO At a Glance

Thermo Fisher Scientific, Inc.
168 Third Avenue
Waltham, Massachusetts 02451
Phone 1-781-622-1000 Revenue 42.86B
Industry Medical Specialties Net Income 6.00B
Sector Health Technology Employees 122,000
Fiscal Year-end 12 / 2024
View SEC Filings

TMO Valuation

P/E Current 31.928
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 34.353
Price to Sales Ratio 4.805
Price to Book Ratio 4.391
Price to Cash Flow Ratio 24.50
Enterprise Value to EBITDA 21.599
Enterprise Value to Sales 5.469
Total Debt to Enterprise Value 0.155

TMO Efficiency

Revenue/Employee 351,286.885
Income Per Employee 49,139.344
Receivables Turnover 4.435
Total Asset Turnover 0.438

TMO Liquidity

Current Ratio 1.755
Quick Ratio 1.392
Cash Ratio 0.577

TMO Profitability

Gross Margin 40.119
Operating Margin 17.374
Pretax Margin 14.695
Net Margin 13.988
Return on Assets 6.121
Return on Equity 13.218
Return on Total Capital 7.209
Return on Invested Capital 7.812

TMO Capital Structure

Total Debt to Total Equity 77.937
Total Debt to Total Capital 43.80
Total Debt to Total Assets 36.894
Long-Term Debt to Equity 69.652
Long-Term Debt to Total Capital 39.144
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Thermo Fisher Scientific Inc. - TMO

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
32.22B 39.21B 44.91B 42.86B
Sales Growth
+26.14% +21.71% +14.55% -4.58%
Cost of Goods Sold (COGS) incl D&A
16.19B 19.58B 25.90B 25.66B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.33B 2.59B 3.38B 3.41B
Depreciation
658.00M 831.00M 986.00M 1.07B
Amortization of Intangibles
1.67B 1.76B 2.40B 2.34B
COGS Growth
+14.04% +20.91% +32.32% -0.93%
Gross Income
16.03B 19.63B 19.01B 17.19B
Gross Income Growth
+41.28% +22.51% -3.17% -9.56%
Gross Profit Margin
+49.75% +50.07% +42.33% +40.12%
2020 2021 2022 2023 5-year trend
SG&A Expense
8.04B 9.32B 10.49B 9.75B
Research & Development
1.18B 1.41B 1.47B 1.34B
Other SG&A
6.86B 7.91B 9.02B 8.41B
SGA Growth
+13.77% +15.90% +12.56% -7.04%
Other Operating Expense
- - - 63.00M
-
Unusual Expense
(27.00M) 865.00M 131.00M 496.00M
EBIT after Unusual Expense
7.95B 9.45B 8.39B 6.95B
Non Operating Income/Expense
(175.00M) (76.00M) 167.00M 839.00M
Non-Operating Interest Income
65.00M 43.00M 272.00M 879.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
553.00M 536.00M 726.00M 1.49B
Interest Expense Growth
-18.20% -3.07% +35.45% +105.37%
Gross Interest Expense
553.00M 536.00M 726.00M 1.49B
Interest Capitalized
- - - -
-
Pretax Income
7.22B 8.84B 7.83B 6.30B
Pretax Income Growth
+77.52% +22.37% -11.38% -19.62%
Pretax Margin
+22.43% +22.55% +17.44% +14.70%
Income Tax
850.00M 1.11B 703.00M 284.00M
Income Tax - Current - Domestic
696.00M 606.00M 1.07B 378.00M
Income Tax - Current - Foreign
423.00M 1.15B 633.00M 1.21B
Income Tax - Deferred - Domestic
(251.00M) (246.00M) (683.00M) (653.00M)
Income Tax - Deferred - Foreign
(18.00M) (399.00M) (314.00M) (647.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.38B 7.73B 6.96B 5.96B
Minority Interest Expense
- 3.00M 10.00M (40.00M)
Net Income
6.38B 7.72B 6.95B 6.00B
Net Income Growth
+72.48% +21.18% -10.03% -13.74%
Net Margin Growth
+19.79% +19.70% +15.47% +13.99%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
6.38B 7.72B 6.95B 6.00B
Preferred Dividends
- - - -
-
Net Income Available to Common
6.38B 7.72B 6.95B 6.00B
EPS (Basic)
16.0985 19.6066 17.7296 15.5311
EPS (Basic) Growth
+74.23% +21.79% -9.57% -12.40%
Basic Shares Outstanding
396.00M 394.00M 392.00M 386.00M
EPS (Diluted)
15.9774 19.4584 17.6396 15.451
EPS (Diluted) Growth
+74.21% +21.79% -9.35% -12.41%
Diluted Shares Outstanding
399.00M 397.00M 394.00M 388.00M
EBITDA
10.25B 12.91B 11.91B 10.85B
EBITDA Growth
+56.84% +25.94% -7.78% -8.85%
EBITDA Margin
+31.82% +32.92% +26.51% +25.32%

Snapshot

Average Recommendation BUY Average Target Price 660.542
Number of Ratings 31 Current Quarters Estimate 5.939
FY Report Date 12 / 2024 Current Year's Estimate 21.693
Last Quarter’s Earnings 5.28 Median PE on CY Estimate N/A
Year Ago Earnings 21.55 Next Fiscal Year Estimate 23.552
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 19 27 28
Mean Estimate 5.94 5.44 21.69 23.55
High Estimates 6.08 5.68 21.88 24.40
Low Estimate 5.70 5.15 21.46 22.99
Coefficient of Variance 1.43 2.65 0.44 1.53

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 21 20 18
OVERWEIGHT 5 5 4
HOLD 5 6 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Overweight Overweight

Insider Actions for Thermo Fisher Scientific Inc. - TMO

Date Name Shares Transaction Value
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 129,716 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $596.35 per share 77,356,136.60
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 125,327 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $612.92 per share 76,815,424.84
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 125,900 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $611.2 per share 76,950,080.00
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 126,896 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $609.87 per share 77,390,063.52
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 128,396 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $609.07 per share 78,202,151.72
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 129,060 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $607.48 per share 78,401,368.80
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 129,260 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $606.74 per share 78,427,212.40
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 130,118 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $605.57 per share 78,795,557.26
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 132,103 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $604 per share 79,790,212.00
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 133,816 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $210.68 per share 28,192,354.88
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 123,816 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $607.67 per share 75,239,268.72
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 123,886 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $606.88 per share 75,183,935.68
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 124,188 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $605.78 per share 75,230,606.64
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 124,980 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $604.54 per share 75,555,409.20
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 126,018 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $603.38 per share 76,036,740.84
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 127,018 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $601.29 per share 76,374,653.22
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 127,218 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $600.05 per share 76,337,160.90
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 129,116 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $598.84 per share 77,319,825.44
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 129,516 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $597.36 per share 77,367,677.76
Aug 1, 2024 Marc N. Casper Chairman & CEO; Director 130,116 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $190.59 per share 24,798,808.44

Thermo Fisher Scientific Inc. in the News